Moneycontrol PRO
Check Credit Score
Check Credit Score
HomeNewsBusinessCompanies

Exclusive | Zydus Cadila expects to launch Remdesivir in August: Chairman Pankaj Patel

Chairman Pankaj Patel said Zydus Cadila has potential to produce as high as 3-4 lakh doses a month.

July 17, 2020 / 07:45 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Pankaj Patel, Chairman of Zydus Cadila, said the company expects to launch antiviral drug Remdesivir early next month and has the potential to produce as high as 3-4 lakh doses a month.

Zydus has a voluntary license from Gilead Sciences to manufacture and distribute the drug in 127 countries including India.

The company has sought approval from the Drug Controller General of India (DCGI), the application is currently under review, Patel told in an interview to Moneycontrol.

Cipla, Hetero and Mylan have till now launched the generic versions of Remdesivir in India. Both Cipla and Hetero can produce up to 2 lakh doses a month; the production capacity of Mylan is not known. Jubilant Life Sciences, Dr Reddy's, Syngene are other companies that have licenses from Gilead to manufacture and distribute Remdesivir generic versions but are yet to get approval from DCGI.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Remdesivir is prescribed for hospitalised patients who are on oxygen. The drug has to take for five days, 200 mg IV (intravenous) on day 1 followed by 100 mg IV daily for four days.

With a rising number of confirmed COVID-19 cases, the demand for Remdesivir is also soaring, but the current capacity is still way short than the demand. Prices of the drug in the black market have soared many times its MRP. 

According to John Hopkins University COVID-19 tracker, COVID-19 cases in India crossed 1 million-mark with 25,602 deaths. There are around 3.5 lakh active cases, which are increasing by around 30,000 per day. About 20 percent of all COVID-19 cases would require hospitalisation, and fit case for the administration of Remdesivir.

On the possibility of working on a different formulation of Remdesivir like inhalation route, Patel said they have the capability of developing an inhalation formulation, but not working on any formulation other than the intravenous (IV) route.

"We are working to make Remdesivir available," Patel said.

Gilead, the innovator of Remdesivir is testing the inhaled version of Remdesivir to treat COVID-19 patients in the outpatient setting, and at a more early stage.

SARS-CoV-2 infects the upper respiratory tract in the early stages of the disease; an inhaled version is considered to be more convenient and effective.

Viswanath Pilla
Viswanath Pilla is a business journalist with 14 years of reporting experience. Based in Mumbai, Pilla covers pharma, healthcare and infrastructure sectors for Moneycontrol.
first published: Jul 17, 2020 02:07 pm

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347